scholarly journals A clinical nomogram and heat map for assessing survival in patients with stage I non-small cell lung cancer after complete resection

2020 ◽  
Vol 12 ◽  
pp. 175883592097006
Author(s):  
Xun Cao ◽  
Yu-zhen Zheng ◽  
Hong-ying Liao ◽  
Xiang Guo ◽  
Yong Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Complete Resection ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Heat Map ◽  
Risk Patients

Background: Assessing the prognosis of patients with early-stage non-small cell lung cancer (NSCLC) has become a major clinical issue. This study aimed to devise an effective clinical nomogram and heat map for assessing the survival of patients with stage I NSCLC receiving complete resection. Methods: Nomograms were established based on a retrospective study of 654 patients with stage I NSCLC who underwent radical resection at Sun Yat-Sen University Cancer Center between January 2009 and December 2014. The concordance index (C-index) and calibration curve were used to measure the accuracy and discriminative ability of the final nomogram. Heat maps were constructed with prognostic factors and survival probabilities. Survival curves were depicted using the Kaplan–Meier method, and the log-rank test was used to determine significance. Patients were classified into low- and high-risk subgroups using recursive partitioning analysis based on nomogram scores. Results: In univariate and multivariate analyses, the independent factors for overall survival (OS) and disease-free survival (DFS) were age, sex, tumor size, and visceral pleural invasion, which were all selected in the nomogram. The C-indices of the nomogram for predicting OS and DFS were 0.694 [95% confidence interval (CI) 0.651–0.737] and 0.653 (95% CI 0.61–0.696), respectively. The calibration curves for OS and DFS probabilities showed a good agreement between the nomogram prediction and actual observation. A heat map was generated using the above independent factors for OS and DFS. High-risk patients had shorter OS [hazard ratio (HR) = 3.535, 95% CI 2.444–5.113, p < 0.001] and DFS (HR = 2.607, 95% CI 1.922–3.537, p < 0.001) than low-risk patients. Conclusion: We established a prognostic nomogram and heat map that can be useful for evaluating survival in patients with stage I NSCLC after complete resection. The tools resulted in more accurate prediction and may guide clinicians in making treatment decisions.

Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non–small-cell lung cancer

Surgery ◽  
2003 ◽  
Vol 134 (4) ◽  
pp. 691-697 ◽  
Author(s):  
Ricardo Santos ◽  
Athanasios Colonias ◽  
David Parda ◽  
Mark Trombetta ◽  
Richard H Maley ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Sublobar Resection ◽  
Small Cell Lung ◽  
High Risk Patients ◽  
Risk Patients

scholarly journals Proton Beam Therapy for High-risk Patients with Stage I Non-Small Cell Lung Cancer

2016 ◽  
Vol 96 (2) ◽  
pp. E457-E458
Author(s):  
K. Ohnishi ◽  
T. Okumura ◽  
H. Ishikawa ◽  
Y. Oshiro ◽  
M. Mizumoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Proton Beam ◽  
Cell Lung Cancer ◽  
Proton Beam Therapy ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Risk Patients

scholarly journals Comparison of Limited Surgery and Three-Dimensional Conformal Radiation in High-Risk Patients with Stage I Non-small Cell Lung Cancer

2007 ◽  
Vol 2 (11) ◽  
pp. 1022-1028 ◽  
Author(s):  
Sai Yendamuri ◽  
Ritsuko R. Komaki ◽  
Arlene M. Correa ◽  
Pamela Allen ◽  
Bob Wynn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Three Dimensional ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Limited Surgery ◽  
Risk Patients

scholarly journals Stereotactic radiosurgery for the treatment of stage I non–small cell lung cancer in high-risk patients

2009 ◽  
Vol 137 (3) ◽  
pp. 597-604 ◽  
Author(s):  
Arjun Pennathur ◽  
James D. Luketich ◽  
Dwight E. Heron ◽  
Ghulam Abbas ◽  
Steven Burton ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Stereotactic Radiosurgery ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
High Risk Patients ◽  
Risk Patients

scholarly journals Radiofrequency ablation for the treatment of stage I non–small cell lung cancer in high-risk patients

2007 ◽  
Vol 134 (4) ◽  
pp. 857-864 ◽  
Author(s):  
Arjun Pennathur ◽  
James D. Luketich ◽  
Ghulam Abbas ◽  
Mang Chen ◽  
Hiran C. Fernando ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiofrequency Ablation ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
High Risk Patients ◽  
Risk Patients

Robotic Radiosurgery: An Effective Alternative to Wedge Resection for High-Risk Patients With Peripheral Stage I Non-small Cell Lung Cancer

CHEST Journal ◽  
2010 ◽  
Vol 138 (4) ◽  
pp. 885A
Author(s):  
Brian T. Collins ◽  
Eric K. Oermann ◽  
Saloomeh Vahdat ◽  
Simeng Suy ◽  
Yu Xia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Wedge Resection ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Robotic Radiosurgery ◽  
Risk Patients

scholarly journals Preoperative nivolumab to evaluate pathological response in patients with stage I non-small cell lung cancer: a study protocol of phase II trial (POTENTIAL)

BMJ Open ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. e043234
Author(s):  
Atsushi Kagimoto ◽  
Yasuhiro Tsutani ◽  
Takahiro Mimae ◽  
Yoshihiro Miyata ◽  
Norihiko Ikeda ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Phase Ii Trial ◽  
Clinical Stage ◽  
Small Cell ◽  
Pathological Response ◽  
Stage I ◽  
Small Cell Lung

IntroductionRecently, inhibition of programmed cell death 1 or its ligand has shown therapeutic effects on non-small cell lung cancer (NSCLC). However, the effectiveness of preoperative nivolumab monotherapy for stage I NSCLC remains unknown. The present study aimed to investigate the pathological response of preoperative treatment with nivolumab for clinically node negative but having a high risk of NSCLC recurrence.Methods and analysisThe Preoperative Nivolumab (Opdivo) to evaluate pathologic response in patients with stage I non-small cell lung cancer: a phase 2 trial (POTENTIAL) study is a multicentre phase II trial investigating efficacy of preoperative nivolumab for clinical stage I patients at high risk of recurrence. This study includes histologically or cytologically confirmed NSCLC patients with clinical N0 who were found on preoperative high-resolution CT to have a pure solid tumour without a ground-glass opacity component (clinical T1b, T1c or T2a) or a solid component measuring 2–4 cm in size (clinical T1c or T2a). Patients with epidermal growth factor receptor (EGFR) mutation (deletion of exon 19 or point mutation on exon21, L858R), anaplastic lymphoma kinase (ALK) translocation or c-ros oncogene 1 (ROS-1) translocation are excluded from this study. Nivolumab (240 mg/body) is administrated intravenously as preoperative therapy every 2 weeks for three cycles. Afterward, lobectomy and mediastinal lymph node dissection (ND 2a-1 or ND 2a-2) are performed. The primary endpoint is a pathological complete response in the resected specimens. The secondary endpoints are safety, response rates and major pathological response. The planed sample size is 50 patients. Patients have been enrolled since April 2019.Ethics and disseminationThis trial was approved by the Institutional Review Board of Hiroshima University Hospital and other participating institutions. This trial will help examine the efficacy of preoperative nivolumab therapy for clinical stage I NSCLC.Trial registration numberjRCT2061180016.

Sign in / Sign up

Export Citation Format

Share Document